Clinical Trials Logo

Cholangiocarcinoma clinical trials

View clinical trials related to Cholangiocarcinoma.

Filter by:

NCT ID: NCT03368963 Not yet recruiting - Clinical trials for Stage IV Pancreatic Cancer

TAS102 in Combination With NAL-IRI in Advanced GI Cancers

Start date: December 1, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the best dose and how well trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) and nanoliposomal irinotecan work in treating patients with gastrointestinal cancers that have spread to other places in the body or cannot be removed by surgery. Drugs used in the chemotherapy, such as trifluridine/tipiracil hydrochloride combination agent TAS-102 and nanoliposomal irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

NCT ID: NCT03364530 Not yet recruiting - Clinical trials for Cholangiocarcinoma Non-resectable

Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma

GEMOXIA-02
Start date: January 2018
Phase: Phase 2
Study type: Interventional

We hypothesized that intra-arterial gemcitabine/oxaliplatin administered as second-line treatment could strongly improve objective response rate at 4 months after inclusion in patient with non-metastatic unresectable intra-hepatic cholangiocarcinoma.

NCT ID: NCT03345303 Recruiting - Clinical trials for Intrahepatic Cholangiocarcinoma

Bortezomib in Intrahepatic Cholangiocellular Carcinoma

Start date: January 2017
Phase: Phase 3
Study type: Interventional

This study evaluates the efficacy and safety of second-line treatment of bortezomib in advanced intrahepatic cholangiocarcinoma patients.Half of participants will receive bortezomib while the other half will receive best supporting care.

NCT ID: NCT03339843 Not yet recruiting - Endometrial Cancer Clinical Trials

Multiorgan Metabolic Imaging Response Assessment of Abemaciclib

MiMe-A
Start date: February 15, 2018
Phase: Phase 2
Study type: Interventional

Open-label, phase II, basket trial. This trial is a screening program for abemaciclib efficacy in multiple platinum-resistant tumour types by using metabolic imaging (PERCIST) and RECIST v1.1 criteria. Based on the rate of FDG-avidity and the absence of deactivation of the Rb gene function in more than 95% of cases, we propose to define 5 tumour types of interest in a preliminary stage: 1. Platinum-refractory esophageal adenocarcinoma (ADC) 2. Platinum-refractory esophageal squamous cell carcinoma (SCC) 3. Platinum-refractory cholangiocarcinoma 4. Platinum-refractory and progressive after immunotherapy urothelial cancer 5. Platinum-refractory endometrial cancer

NCT ID: NCT03338062 Recruiting - Clinical trials for Hepatocellular Carcinoma

A Pilot Study to Assess Theragnostically Planned Liver Radiation With Functional DVH Analysis to Optimize Individualized Radiation Therapy

Start date: June 13, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to compare radiation treatment plans that are designed for patients with liver cancer. One treatment plan will be created using routine procedures and scans normally performed for radiation treatment planning. The other treatment plan will be created using routine procedures with the addition of two imaging scans; a HIDA (Hepatobiliary Iminodiacetic Acid) scan and an MRI (Magnetic Resonance Imaging) scan. This study will evaluate if adding these imaging scans to treatment planning can reduce the amount of radiation to healthy liver tissue during treatment.

NCT ID: NCT03329950 Recruiting - Breast Cancer Clinical Trials

A Study of CDX-1140 in Patients With Advanced Solid Tumors

Start date: December 2017
Phase: Phase 1
Study type: Interventional

This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 and to further evaluate its tolerability and efficacy in expansion cohorts once the MTD is determined.

NCT ID: NCT03320980 Completed - Clinical trials for Intrahepatic Cholangiocarcinoma

RALPPS in Patients With Hilar and Intrahepatic Cholangiocarcinoma

Start date: September 15, 2014
Phase: N/A
Study type: Observational

Unsatisfactory immediate outcomes of Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) in surgery of cholangiocarcinoma suggested that patients with biliary cancer should not be treated by ALPPS. Short-term results of ALPPS variants with reduced surgical trauma on the first stage in patients with cholangiocarcinoma were not yet estimated. The objective of the study was estimation of the short-term results of split-in-situ resection with radio-frequency ablation (RFA) instead of liver partition on the first stage (RALPPS) in patients with hilar (h-CCA) and intrahepatic (i-CCA) cholangiocarcinoma compared with portal vein embolization (PVE).

NCT ID: NCT03307538 Recruiting - Klatskin Tumor Clinical Trials

Stereotactic Body Radiation Therapy for Unresectable Perihilar Cholangiocarcinoma

STRONG
Start date: November 6, 2017
Phase: N/A
Study type: Interventional

Rationale: For patients with perihilar cholangiocarcinoma, surgery is the only treatment modality that can result in cure. Unfortunately, in the majority of these patients the tumors are found to be unresectable at presentation due to local invasive tumor growth or the presence of distal metastases. For patients with unresectable cholangiocarcinoma palliative chemotherapy is the standard treatment yielding an estimated median overall survival of 12-15.2 months. There is no evidence from randomized trials that support the routine use of stereotactic body radiation therapy (SBRT) for cholangiocarcinoma. However, small and most often retrospective studies combining chemotherapy with SBRT showed promising results with overall survival reaching up to 33-35 months. Based upon these observations, the investigators designed a local feasibility trial with SBRT after chemotherapy in patients with unresectable perihilar cholangiocarcinoma in order to try to confirm the observed tolerability of adding SBRT to standard chemotherapy. The expected time to include the required patients for this pilot study will be one year. Objective: To assess feasibility of SBRT as add on treatment after standard chemotherapy. Study design: Local feasibility trial. Study population: Patients diagnosed with perihilar cholangiocarcinoma, 18 years of age or older, T1-4 N0-1 M0 (AJCC 7th Edition), after completion of standard chemotherapy. Exclusion criteria are local tumor growth into either stomach, colon, duodenum, pancreas or abdominal wall. Sample size will be 6 patients. Intervention: SBRT will be delivered in 15 fractions of 3 to 4.5Gy after 8 cycles of chemotherapy. In case of toxicity causing premature termination of systemic treatment, the patient can still proceed to SBRT. Main study parameters/endpoints: The primary endpoint of this study is feasibility measured by radiotherapy induced toxicity according to CTC v4.0.3. Secondary endpoints will be: - Quality of life - Local progression - Progression free survival - Overall survival - Cellular radiosensitivity.

NCT ID: NCT03278106 Recruiting - Cholangiocarcinoma Clinical Trials

TAS-102 in Treating Advanced Biliary Tract Cancers

Start date: October 20, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) works in treating participants with biliary tract cancers that have spread to other places in the body. Drugs used in the chemotherapy, such as trifluridine/tipiracil hydrochloride combination agent TAS-102, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

NCT ID: NCT03267966 Active, not recruiting - Pancreatic Cancer Clinical Trials

Margin Status After Pancreaticoduodenectomy for Cancer

Start date: March 2013
Phase: N/A
Study type: Interventional

The study evaluates if a standardized method of pathological evaluation of the specimen affects the R1 resection rate after Pancreatico-Duodenectomy (PD) for cancer.